Lebrikizumab in Atopic Dermatitis: Associations of Patient Characteristics and Treatment History with Clinical Outcomes. (PubMed, Dermatitis) - Sep 24, 2026 - "Lebrikizumab demonstrated favorable real-world effectiveness and safety in adults with moderate-to-severe AD after 16 weeks of treatment, with clinical and patient-reported improvements maintained through week 24."
Clinical data • Journal • Atopic Dermatitis • CNS Disorders • Conjunctivitis • Dermatitis • Dermatology • Immunology • Ocular Infections • Ocular Inflammation • Ophthalmology • Pruritus • Sleep Disorder
|
|
Alessandra Capo; Anna Campanati; Benedetta Ambrosio; Camilla Chello; Edoardo Mortato; Elena Ippoliti; Elettra Antonelli; Emanuela Martina; Ersilia Tolino; Ester Del Duca; Gaia Moretta; Ketty Peris; Lina Maria Magnanimi; Luca Stingeni; Lucia Di Nardo; Marco Galluzzo; Maria Concetta Fargnoli; Maria Esposito; Maria Mariano; Nevena Skroza; Niccolò Gori; Ornella De Pità; Paolo Amerio
|